Details for New Drug Application (NDA): 207518
✉ Email this page to a colleague
The generic ingredient in AZACITIDINE is azacitidine. There are fifteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the azacitidine profile page.
Summary for 207518
| Tradename: | AZACITIDINE |
| Applicant: | Shilpa Medicare |
| Ingredient: | azacitidine |
| Patents: | 0 |
Pharmacology for NDA: 207518
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 207518
Suppliers and Packaging for NDA: 207518
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207518 | ANDA | Dr. Reddy's Laboratories Inc. | 43598-678 | 43598-678-11 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (43598-678-11) |
| AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207518 | ANDA | Fresenius Kabi USA, LLC | 63323-771 | 63323-771-39 | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-771-39) / 30 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS, SUBCUTANEOUS | Strength | 100MG/VIAL | ||||
| Approval Date: | Sep 29, 2016 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
